Table 3.

Comparison of g-rates of drugs used in 1st line in the olaparib cohort and in a matched reference cohort.^a

	Abiraterone		Enzalutamide		Docetaxel
	Olaparib cohort [N = 59]b	Reference cohort [N = 175]b	Olaparib cohort [N = 41]b	Reference cohort [N = 117]b	Olaparib cohort [N = 16]b	Reference cohort [N = 45c]b
Age, median, IQR, years	71 [67–75]	73 [71–78]	72 [70–80]	74 [71–81]	68 [60–69]	70 [64–73]
Age group, years
<65	2 [3%]	6 [3%]	3 [7%]	9 [8%]	4 [25%]	12 [27%]
65–69	7 [12%]	20 [11%]	0 [0%]	0 [0%]	2 [13%]	6 [13%]
70–74	25 [42%]	75 [43%]	18 [44%]	54 [46%]	7 [44%]	21 [47%]
75–79	13 [22%]	39 [22%]	8 [20%]	18 [15%]	3 [19%]	6 [13%]
$\ge$ 80	12 [20%]	35 [20%]	12 [29%]	36 [31%]	0 [0%]	0 [0%]
Race
White	44 [75%]	131 [75%]	26 [63%]	75 [64%]	9 [56%]	27 [60%]
Black	12 [20%]	36 [21%]	12 [29%]	36 [31%]	6 [38%]	15 [33%]
Other/Unknown	3 [5%]	8 [5%]	3 [7%]	6 [5%]	1 [6%]	3 [7%]
Starting PSA, ng/mL	6 [0.71–14]	2 [0.60–9]	5 [0.39–14]	1 [0.50–5]	25 [3–142]	6 [1–37]
Gleason Score
<8	22 [37%]	64 [37%]	14 [34%]	42 [36%]	1 [6%]	3 [7%]
$\ge$ 8	33 [56%]	99 [57%]	25 [61%]	72 [62%]	13 [81%]	36 [80%]
Unknown	4 [7%]	12 [7%]	2 [5%]	3 [3%]	2 [13%]	6 [13%]
Comorbidity index
<5	49 [83%]	146 [83%]	30 [73%]	90 [77%]	13 [81%]	39 [87%]
$\ge$5	10 [17%]	29 [17%]	10 [24%]	27 [23%]	3 [19%]	6 [13%]
Unknown	0 [0%]	0 [0%]	1 [2%]	0 [0%]	0 [0%]	0 [0%]
g-rates/day	0.001357	0.000858	0.001889	0.000607	0.001914	0.001161
p-valued	–	0.34	–	0.002e	–	0.37e

^aMatched on 5 year interval age groups, race, PSA (<1, 1–10, >10), Gleason score (<8, $\ge$ 8) and prior lines of therapy (0,1, $\ge$ 2).

^b59, 41, and 16 of the abiraterone, enzalutamide and docetaxel cohorts had received the cohort-defining drug in the first line and these numbers defined the size of an additional 3:1 cohort. 177 (59 × 3), 123 (41 × 3) 48 (16 × 3) for the abiraterone, enzalutamide and docetaxel cohort, respectively.

^cNo matches were found for one patient, thus only N = 47 was selected from the reference cohort.

^dp-values in each case are obtained by comparing the g-rates of a reference cohort to the olaparib cohort.

^eThese p-values come from Wilcoxon rank-sum test.